ILC2: Initiatives in Lung Cancer Care is a global funding opportunity to transform patient care and improve the patient experience

There remains considerable variation in the management of lung cancer around the world. Access for patients to important diagnostics, treatments and support programmes varies markedly.

The ILC2 programme supports patient and caregiver organisations registered as non-profit/ charity in their country to propose and conduct projects that can potentially transform patient care in countries around the world.

The programme recognises the high variation in lung cancer management around the world, and the very specific local barriers to quality care that must be considered when developing patient centric solutions to address them.

ILC2 grant applications are reviewed and selected by the four founding partners of the Lung Ambition Alliance: the Global Lung Cancer Coalition, Guardant Health, the International Association for the Study of Lung Cancer and AstraZeneca. Funding for the ILC2 grant is provided by AstraZeneca, on behalf of The Lung Ambition Alliance.

ILC2 is looking to fund innovative, promising and proven projects.

Please note: all applications must be completed by 31 December 2020.

See how funding awarded in the first round of grants has assisted projects.